Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CTSV | O60911 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1679975 | 0.88 | MEN1 (0.44) | L3MBTL1MEN1KMT2AMAPTLMNA | |
| SCHEMBL1679945 | 0.86 | TDP1 (0.47) | L3MBTL1MEN1KMT2AMAPTKDM4E | |
| SCHEMBL1679942 | 0.83 | POLB (0.41) | L3MBTL1MEN1KMT2AMAPTKDM4E | |
| SCHEMBL1679895 | 0.82 | LMNA (0.40) | L3MBTL1MEN1KMT2AMAPTKDM4E | |
| SCHEMBL1781038 | 0.79 | MEN1 (0.44) | L3MBTL1MEN1KMT2AMAPTKDM4E | |
| SCHEMBL29729282 | 0.78 | MEN1 (0.54) | L3MBTL1MEN1KMT2AMAPTKDM4E | |
| SCHEMBL874114 | 0.78 | MEN1 (0.54) | L3MBTL1MEN1KMT2AMAPTKDM4E | |
| SCHEMBL2089147 | 0.78 | MEN1 (0.54) | L3MBTL1MEN1KMT2AMAPTKDM4E | |
| SCHEMBL1679898 | 0.77 | TDP1 (0.47) | L3MBTL1MEN1KMT2AMAPTKDM4E | |
| SCHEMBL12310509 | 0.76 | ALDH1A1 (0.54) | L3MBTL1MEN1KMT2AMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2305649-B1 | METHOD FOR PRODUCING 6-ARYLOXYQUINOLINE DERIVATIVE AND INTERMEDIATE THEREOF | NIPPON KAYAKU KK (JP) | 2013-04-24 | — | — | EP | disclosed |
| US-8367833-B2 | Process for producing 6-aryloxyquinoline derivative and intermediate therefor | NIPPON KAYAKU CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20110118468-A1 | PROCESS FOR PRODUCING 6-ARYLOXYQUINOLINE DERIVATIVE AND INTERMEDIATE THEREFOR | MITSUI CHEMICALS CROP & LIFE SOLUTIONS, INC. (JP) | 2011-05-19 | — | — | US | disclosed |
| EP-2305649-A1 | METHOD FOR PRODUCING 6-ARYLOXYQUINOLINE DERIVATIVE AND INTERMEDIATE THEREOF | Nippon Kayaku Co., Ltd. (JP) | 2011-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118468-A1 | PROCESS FOR PRODUCING 6-ARYLOXYQUINOLINE DERIVATIVE AND INTERMEDIATE THEREFOR | FAR1, CYP4F11, WEE2 | L3MBTL1 4063/4885MEN1 2109/4885KMT2A 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.